Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
Study on Three Types of Nucleotide/Nucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure
Third Affiliated Hospital, Sun Yat-Sen University
150 participants
Feb 21, 2019
INTERVENTIONAL
Conditions
Summary
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
Eligibility
Inclusion Criteria5
- Positive hepatitis b surface antigen or hepatitis b virus DNA > 0.5 year;
- Age from 12 to 65 years old;
- Serum total bilirubin level > 10 times upper limit of normal;
- Prothrombin time activity < 40% or prothrombin time international ratio > 1.5；
- Do not receive nucleotide/nucleoside analogues treatment in the past half year.
Exclusion Criteria9
- Other active liver diseases;
- Hepatocellular carcinoma or other malignancy;
- Pregnancy or lactation;
- Human immunodeficiency virus infection or congenital immune deficiency diseases;
- Severe diabetes, autoimmune diseases;
- Other important organ dysfunctions;
- Using glucocorticoid;
- Patients can not follow-up;
- Investigator considering inappropriate.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03920618